Guest Perspective: Elizabeth Joyce, Marketing & Communications Officer, The Michael J. Fox Foundation for Parkinson’s Research
Recruiting volunteers to participate in clinical trials is a well-known and enduring obstacle to research progress, and the effect is staggering: 85 percent of trials across all diseases face delays and 30 percent never even get off the ground due to low enrollment. And Parkinson’s disease (PD) trials are no exception – fewer than 10 percent of Parkinson’s patients participate.
Today, there are more promising Parkinson’s drugs in the development pipeline than we’ve seen in decades, if not ever. In the context of this encouraging progress, the participation of Parkinson’s patients and control volunteers in PD research is critical to sustaining this momentum. Read More